Antithrombotic Therapy after Bioprosthetic Aortic Valve Replacement: A Therapeutic Morass.

Autor:	Gryaznov AA; Aortic Institute at Yale-New Haven Hospital, Yale University School of Medicine, New Haven, Connecticut, USA.; Department of Surgery, Saint Mary's Hospital, Waterbury, Connecticut, USA., Saeyeldin A; Aortic Institute at Yale-New Haven Hospital, Yale University School of Medicine, New Haven, Connecticut, USA., Abdelbaky M; Aortic Institute at Yale-New Haven Hospital, Yale University School of Medicine, New Haven, Connecticut, USA., Zafar MA; Aortic Institute at Yale-New Haven Hospital, Yale University School of Medicine, New Haven, Connecticut, USA., Tanweer M; Aortic Institute at Yale-New Haven Hospital, Yale University School of Medicine, New Haven, Connecticut, USA., Imran M; Aortic Institute at Yale-New Haven Hospital, Yale University School of Medicine, New Haven, Connecticut, USA., Papanikolaou D; Aortic Institute at Yale-New Haven Hospital, Yale University School of Medicine, New Haven, Connecticut, USA., Erben Y; Aortic Institute at Yale-New Haven Hospital, Yale University School of Medicine, New Haven, Connecticut, USA., Zefirova J; Department of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA., Ziganshin BA; Aortic Institute at Yale-New Haven Hospital, Yale University School of Medicine, New Haven, Connecticut, USA.; Department of Surgical Diseases #2, Kazan State Medical University, Kazan, Russian Federation., Elefteriades JA; Aortic Institute at Yale-New Haven Hospital, Yale University School of Medicine, New Haven, Connecticut, USA.
Jazyk:	angličtina
Zdroj:	Cardiology [Cardiology] 2018; Vol. 140 (4), pp. 213-221. Date of Electronic Publication: 2018 Aug 23.
DOI:	10.1159/000490924
Abstrakt:	Valvular heart disease is a common pathologic condition that affects 6 million people in the United States and more than 100 million worldwide. The most common valvular disorder is aortic stenosis. Current American and European guidelines recommend surgical management for symptomatic aortic stenosis with low risk of perioperative complications and endovascular intervention for high-risk patients with multiple comorbidities. Considering the increasing volume of aortic valve replacement (AVR) with biological valves, it is very important to select the appropriate anticoagulant after surgical AVR. In this article, we review the impact of anticoagulation on immediate and remote complications after AVR. (© 2018 S. Karger AG, Basel.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu